Abstract Number: 036 • 2020 Pediatric Rheumatology Symposium
Medication Related Decision-Making in Parents of Children with Juvenile Idiopathic Arthritis
Background/Purpose: Outcomes for juvenile idiopathic arthritis (JIA) have improved with use of disease-modifying anti-rheumatic drugs (DMARDs) and biologics. Despite this, the decision by a parent…Abstract Number: 137 • 2020 Pediatric Rheumatology Symposium
Measuring Decision Conflict in Parents of Children with Juvenile Idiopathic Arthritis When Making the Decision to Begin Disease Modifying Anti-Rheumatic Drugs or Biologic Agents
Background/Purpose: Disease-modifying antirheumatic drugs (DMARDs) and biologic agents are routinely used in the treatment of JIA and JIA-associated uveitis (JIA-AU). Parents are often fearful, however,…Abstract Number: L01 • 2019 ACR/ARP Annual Meeting
Comparative Risk of Hospitalized Serious Infection in Patients with Psoriasis and Psoriatic Arthritis: A Population-Based Multi-Database Study
Background/Purpose: The risk of serious infection when using disease-modifying antirheumatic drugs (DMARDs), including biologic drugs is one of the major concerns for psoriasis/psoriatic arthritis (PsO/PsA)…Abstract Number: L08 • 2019 ACR/ARP Annual Meeting
Tapering of Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs in Rheumatoid Arthritis Patients in Sustained Remission: Results from a Randomized Controlled Trial
Background/Purpose: Sustained remission is the goal of rheumatoid arthritis (RA) care, and more patients reach and maintain this state on conventional synthetic disease modifying anti-rheumatic…Abstract Number: 988 • 2019 ACR/ARP Annual Meeting
Translational Imaging of Treatment Effects for a Novel Anti-TNF-Steroid Antibody Drug Conjugate in a Rat Model of Rheumatoid Arthritis
Background/Purpose: Rheumatoid arthritis (RA) is an inflammatory joint disease of autoimmune etiology. If insufficiently treated, RA leads to joint damage and irreversible disability. Although there…Abstract Number: 2369 • 2019 ACR/ARP Annual Meeting
Treatment Patterns with Disease Modifying Anti-rheumatic Drugs in United States Veterans with Newly Diagnosed Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis
Background/Purpose: Delays in treatment for inflammatory arthritis (IA) are associated with unfavorable outcomes, including impaired quality of life, irreversible joint damage, and disability. Our objective…Abstract Number: 1194 • 2019 ACR/ARP Annual Meeting
Can an MDHAQ (Multidimensional Health Assessment Questionnaire) 60-Symptom Checklist to Monitor Early Medication Outcomes (MDHAQ/MEMO60) Detect Adverse Events of High-Risk Medications?
Background/Purpose: Adverse events of medications have been reported to account for 5% of hospital admissions in the US, and as many as 10% in the…Abstract Number: 2394 • 2019 ACR/ARP Annual Meeting
Use and Influence of Biologic/Janus Kinase Monotherapy Among Recently Switched Rheumatoid Arthritis Patients: Results from an Annual National Patient Chart Audit
Background/Purpose: US rheumatologists have long agreed that methotrexate (MTX) is the backbone of rheumatoid arthritis (RA) treatment, and while comfort with biologic/JAK monotherapy is growing,…Abstract Number: 1334 • 2019 ACR/ARP Annual Meeting
Patterns of Fatigue in Rheumatoid Arthritis Patients Who Received Biological and Targeted Synthetic Disease-Modifying Antirheumatic Drugs
Background/Purpose: Fatigue is one of the most frequent symptoms in patients with rheumatoid arthritis (RA), affecting more than 80% of them. The experience of fatigue…Abstract Number: 2404 • 2019 ACR/ARP Annual Meeting
Does Combined Therapy Affects Adherence in Rheumatoid Arthritis?
Background/Purpose: Treatment adherence in Rheumatoid Arthritis (RA) patients vary from 30 to 80%. It is important to identify the associated factors to a low adherence,…Abstract Number: 1340 • 2019 ACR/ARP Annual Meeting
Patterns of Sustained Remission and Subsequent DMARD Tapering in Early Rheumatoid Arthritis: Data from the Canadian Early Arthritis Cohort
Background/Purpose: Rheumatoid arthritis (RA) treatment emphasizes aggressive titration of disease-modifying antirheumatic drugs (DMARDs) with the goal of achieving disease remission. This often includes the use…Abstract Number: 2479 • 2019 ACR/ARP Annual Meeting
Unmet Treatment Needs in Patients with Psoriatic Arthritis
Background/Purpose: Despite significant advances in the treatment of psoriatic arthritis (PsA), disease control and remission remain a challenge. Research characterizing residual disease burden with current…Abstract Number: 1380 • 2019 ACR/ARP Annual Meeting
Patient Characteristics, Treatment Patterns, and Treatment Persistency in Biologic DMARD-Experienced Rheumatoid Arthritis Patients in a US RA Registry
Background/Purpose: Multiple treatment options are available for patients with RA. ACR guidelines recommend initiating treatment with a conventional synthetic DMARD (csDMARD). If a patient fails…Abstract Number: 2708 • 2019 ACR/ARP Annual Meeting
Effect of Immunogenicity on Efficacy and Safety of Subcutaneous or Intravenous Abatacept in Pediatric Patients with Polyarticular-Course JIA: Findings from Two Phase III Trials
Background/Purpose: Patients (pts) with polyarticular-course JIA (pJIA) may develop anti-drug antibodies (ADAs) in response to biologics.1 Presence of ADAs has been associated with treatment (tmt)…Abstract Number: 1389 • 2019 ACR/ARP Annual Meeting
Treatment Response to Biologic DMARDs in Patients with RA: A Retrospective Analysis of the RISE Registry
Background/Purpose: ACR guidelines recommend treatment for patients with RA based on baseline (BL) disease activity. In patients with an inadequate response to conventional synthetic DMARDs,…
- 1
- 2
- 3
- …
- 24
- Next Page »